FN3 Stock Overview
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Race Oncology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.72 |
| 52 Week High | AU$1.11 |
| 52 Week Low | AU$0.69 |
| Beta | 1.81 |
| 1 Month Change | -3.33% |
| 3 Month Change | -14.71% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -34.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| FN3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.8% | -3.2% | 2.7% |
| 1Y | n/a | -7.9% | 17.0% |
Return vs Industry: Insufficient data to determine how FN3 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how FN3 performed against the German Market.
Price Volatility
| FN3 volatility | |
|---|---|
| FN3 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: FN3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FN3's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Daniel Tillett | www.raceoncology.com |
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.
Race Oncology Limited Fundamentals Summary
| FN3 fundamental statistics | |
|---|---|
| Market cap | €131.00m |
| Earnings (TTM) | -€8.37m |
| Revenue (TTM) | €2.43m |
54.0x
P/S Ratio-15.6x
P/E RatioIs FN3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FN3 income statement (TTM) | |
|---|---|
| Revenue | AU$4.00m |
| Cost of Revenue | AU$2.61m |
| Gross Profit | AU$1.39m |
| Other Expenses | AU$15.21m |
| Earnings | -AU$13.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 34.72% |
| Net Profit Margin | -345.18% |
| Debt/Equity Ratio | 0% |
How did FN3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 11:18 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Race Oncology Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Independent Investment Research (Aust.) Pty Ltd |
| Chris Kallos | MST Financial Services Pty Limited |